Introduction Polycystic ovary syndrome (PCOS) is a heterogeneous and complex disorder of reproductive aged women, which usually causes reproduction and metabolism failure ( 1 , 2 ). It often presents as hyperandrogenism, hyperinsulinemia
Search Results
Angela Köninger, Antonella Iannaccone, Ensar Hajder, Mirjam Frank, Boerge Schmidt, Ekkehard Schleussner, Rainer Kimmig, Alexandra Gellhaus, and Hans Dieplinger
. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) . Human Reproduction 2004 19 41 – 47 . ( https://doi.org/10.1093/humrep/deh098 ) 4 Fauser BC Tarlatzis BC Rebar RW Legro RS Balen
Sanna Mustaniemi, Marja Vääräsmäki, Johan G Eriksson, Mika Gissler, Hannele Laivuori, Hilkka Ijäs, Aini Bloigu, Eero Kajantie, and Laure Morin-Papunen
Introduction Gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS) are the most common endocrine disorders in women of reproductive age. The prevalence of GDM varies from 9% to 25% and the prevalence of PCOS varies from 5
Krzysztof C Lewandowski, Justyna Płusajska, Wojciech Horzelski, Ewa Bieniek, and Andrzej Lewiński
presented in Table 2 . Table 2 Percentile distribution of insulin resistance indices in a group of 478 women with polycystic ovary syndrome. Percentiles HOMA (95% CI) IRI (Belfiore) (95% CI) QUICKI (95% CI) McAuley (95% CI
Thozhukat Sathyapalan, Anne-Marie Coady, Eric S Kilpatrick, and Stephen L Atkin
reduction in insulin resistance especially with weight loss in patients with T2DM will result in normalisation of pancreatic β-cell requirement and even reversal of T2DM ( 9 ). Statins have shown to improve certain features of polycystic ovary syndrome
Xia Wu, Zhiling Li, Wenjiang Sun, and Huan Zheng
Introduction Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting 6–21% of women of reproductive age depending on the population studied and the diagnostic criteria applied ( 1 ). It is characterized by
Angela Köninger, Philippos Edimiris, Laura Koch, Antje Enekwe, Claudia Lamina, Sabine Kasimir-Bauer, Rainer Kimmig, and Hans Dieplinger
Introduction The polycystic ovary syndrome (PCOS) is one of the most frequent endocrine disorders, found in up to 8% of women of reproductive age (1) . According to the Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group, the diagnosis is
Sebastião Freitas de Medeiros, Cinthia Marenza Ormond, Matheus Antônio Souto de Medeiros, Nayara de Souza Santos, Camila Regis Banhara, and Márcia Marly Winck Yamamoto
Introduction After standardization of the diagnostic criteria for polycystic ovary syndrome (PCOS) the hyperandrogenemic phenotype has been found in nearly 80% of patients ( 1 , 2 ). These hyperandrogenemic patients may have their androgen
Sebastião Freitas de Medeiros, Márcia Marly Winck Yamamoto, Matheus Antônio Souto de Medeiros, Bruna Barcelo Barbosa, José Maria Soares Junior, and Edmund Chada Baracat
Introduction Polycystic ovary syndrome (PCOS) has a prevalence ranging from 5 to 20% in women of reproductive age, depending on the population and criteria used for making a definitive diagnosis ( 1 , 2 ). The use of ultrasound may increase
Xingyan Liu, Mei Xu, Min Qian, and Lindong Yang
Introduction Polycystic ovary syndrome (PCOS), characterized by oligo-anovulation, hyperandrogenism and polycystic ovarian morphology ( 1 ), is a heterogeneous endocrine metabolic disorder among which 3–10% of women in reproductive age had